Global Pulmonary Arterial Hypertension (PAH) Treatment Market is thriving due to a rising prevalence of pulmonary hypertension, advancements in drug development, increasing awareness about the disease ...

Teva's transformation boosts profit growth and specialty drugs, offering an undervalued opportunity. Click here to read my ...

Teva Pharmaceutical Industries TEVA reported second-quarter 2025 adjusted earnings of 66 cents per share, which beat the ...

Bristol-Myers Squibb offers strong cash flow, solid growth, and a high yield despite pricing pressure and pipeline risks.

Check out our PLTR stock chart to see a history of performance, current stock value, and a timeline of financial events & indicators for a full analysis today.